vTv Therapeutics expands Newsoara license globally for $20M upfront, up to $96M milestones

vTv Therapeutics Inc.

Second Amendment to License Agreement with Newsoara Biopharma expands original China license to global.
Newsoara to pay $20M upfront within one year; if not paid, amendment void.
Up to $41M in development milestones and $35M in sales milestones, plus mid-to-upper single-digit royalties.
vTv Therapeutics LLC (subsidiary of vTv Therapeutics Inc.) is the licensor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.